Biobeat Wearable Wrist and Chest Patient Monitoring Solutions Receives Class II Medical Device Approval from Health Canada

October 27, 2020

Biobeat provides wearable remote patient monitoring solutions for the healthcare continuum. Today they announced today that its wearable wrist and chest patient monitoring solutions have received Class II medical device approval (No. 320337) from Health Canada.

Biobeat reports their wireless wrist and chest monitoring solutions support health teams by transmitting real-time patient data from a distance, helping improve patient outcomes via accurate and reliable patient health updates and patient deterioration detection. These remote capabilities can be instrumental in helping monitor a variety of health conditions as well as mitigating the risk of infectious exposure, especially from COVID-19 patients.

“We are excited to receive the Health Canada Medical Device Class II approval, a significant milestone for our company, which will allow us to offer our innovative technologies to the Canadian healthcare market and help improve patient care,” said Arik Ben Ishay, CEO of Biobeat. “This registration underscores our mission to improve patient outcomes across the globe with our accurate wearable continuous patient monitoring solutions. We are eager to assist Canadian healthcare facilities and medical staff manage their patient workloads by using our advanced remote care abilities, especially during the current coronavirus pandemic.”

Maisha Labs, a Canadian digital health solution provider and integrator, assisted Biobeat throughout the licensing process and will continue to play a pivotal role in implementing the company’s solutions in healthcare facilities throughout the country. This includes an upcoming pilot project at The Jewish General Hospital and its Montreal-based Connected Health Futures Hub – OROT, orchestrated by a joint collaboration between Biobeat, Maisha Labs and the TransMedTech Institute, which will use Biobeat’s devices in a remote chronic care program.

Biobeat’s wearable wrist and chest-monitors utilize proprietary non-invasive reflective photoplethysmography monitoring technology to automatically and continuously track multiple vital signs and health parameters. The wireless solutions connect to a cloud-based patient management system to provide medical staff with real-time data and alerts, enabling early identification of clinical deterioration. The management platform includes an integrated automated, customizable early warning score system that incorporates advanced health-AI-based algorithms that analyze aggregated patient data to identify deterioration more accurately.

SourceBiobeat

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”